Xarelto Lawsuit Allegations Question Anticoagulant’s Rare One-Pill-Per-Day Dosage

April 20, 2016 – – BloodThinnerHelp.com reports on the details of one of the thousands of lawsuits which has been filed against Xarelto manufacturers Janssen Pharmaceuticals (a subdivision of Johnson & Johnson) and Bayer AG. This lawsuit is especially notable as its allegations differ from most of the rest. It was filed in a Pennsylvania State Court. Most of the thousands of Xarelto lawsuit complaints that currently exist were filed against the same defendants but instead referenced the anticoagulant’s alleged sudden bleeding episode dangers. However, this lawsuit brings up another concern: the drug’s one-pill-per-day, one-dose-for-all instructions.

Out of many blood thinners, Xarelto is the only one to offer a single pill dose. Most blood-thinning drugs instruct that users take 2 pills each day to properly ensure they will remain medicated for a full 24-hours. This plaintiff’s lawsuit indicates that this recommended once-daily dosage is ineffective in protecting patients for a full day. The plaintiff alleged this after unexpectedly suffering from a stroke just four days after beginning to use Xarelto in order to prevent strokes, which he was deemed to be at heightened risk for due to a heart condition called atrial fibrillation.

Atrial fibrillation is a fairly common heart condition which can cause patient’s heart rates to be faster than normal. This can put patients at increased risk of stroke, and therefore, patients with this condition have been approved for treatment with blood thinners. After suffering a stroke, the plaintiff filed his lawsuit in Pennsylvania on October 8, 2015. As the first lawsuit of its kind, his allegations have drawn increased public attention and have raised new concerns regarding use of the drug. In addition to claiming that the blood thinner failed to prevent his stroke, the plaintiff has alleged that the drug may have actually caused it.

After approval by the U.S. Food and Drug Administration in 2011, Xarelto was released to the market for public sale and thought of as a revolutionary, new-generation blood thinner. It reportedly became a billion dollar product for the manufacturer, and was popular, as it could provide those in need of blood-thinning drugs with new freedoms that traditional blood thinners could not. While traditional blood thinners often required regular physician monitoring, dosage adjustments, and certain diets, Xarelto did not. It was heavily marketed and many current plaintiffs have claimed that the marketing was misleading, and that the manufacturers did not properly note the drug’s potentially dangerous and life-threatening side effects.

Plaintiffs who have submitted federally-filed Xarelto lawsuits have had their complaints transferred and consolidated to a single court in Eastern Louisiana by the U.S. Judicial Panel on Multidistrict Litigation, forming MDL No. 2592. The lawsuits are being overseen by the Honorable Judge Eldon Fallon. As the involved plaintiffs anxiously await bellwether trials scheduled for early 2017, Attorney Joseph Osborne is working to help others who have taken the drug and who feel that it has negatively impacted their health. He feels that it is important for all affected patients to explore their legal rights in the matter, as they may be entitled to significant compensation gained through legal action. To better help those wishing to learn more about their legal options, Attorney Osborne is currently offering free legal consultations to qualified parties.

To ask questions, or request additional Xarelto lawsuit information, please contact Joseph Osborne, Esq. by calling (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60009476